Listen on the go
    • Faculty & Disclosures
    Prof. Simona Sacco

    University of L’Aquila, Italy

    Simona Sacco is professor of neurology at the University of L’Aquila in Italy and director of the local clinical neurology and stroke unit. read more

    Prof. Sacco is author of more than 270 publications in the field of stroke and headache. She is the president elect of the European Stroke Organisation and second vice-president of the European Headache Federation (EHF). She is currently the chief editor for the Headache and Neurogenic Pain section in Frontiers in Neurology, associate editor for the Journal of Headache and Pain, assistant editor for Stroke and member of the editorial board of Neurology. She has chaired the EHF guideline on the use of monoclonal antibodies targeting the calcitonin gene-related peptide for migraine prevention, the EHF consensus on resistant and refractory migraine and the EHF consensus on triptan non-responders.

    Professor Simona Sacco discloses: Personal fees as speaker or advisor from Abbott, Allergan-AbbVie, AstraZeneca, Eli Lilly, Lundbeck, Novartis, Novo Nordisk, Pfizer and Teva Pharmaceuticals. Research grants from Novartis. Fees for CME/education from Medscape, Neurodiem and Ology Medical Education.
    Ms Elena Ruiz de la Torre

    European Migraine & Headache Alliance, Valencia, Spain

    Ms Elena Ruiz de la Torre is a world-renowned patient advocate, researcher and executive director of the European Migraine & Headache Alliance.read more

    She tirelessly and passionately advocates for people living with headache disorders in the workplace and beyond, with her advocacy career beginning in Spain. She also co-led the creation of the World Headache and Migraine Alliance, a patient-led coalition open to patient groups around the world. She has co-authored several publications, and her list of current advocacy work is extensive, including the “My Migraine Voice” global survey, the European “Migraine at Work” and “Access to Care” surveys, and the “Migraine Matters” project.

    Ms Elena Ruiz de la Torre has no interests/relationships or affiliations to disclose in relation to this activity.
    Prof. Mamoru Shibata

    Tokyo Dental College, Ichikawa General Hospital, Chiba, Japan

    Prof. Mamoru Shibata is professor of neurology at the Tokyo Dental College, Ichikawa General Hospital, Chiba, Japan. read more

    He obtained his PhD degree from Keio University Graduate School of Medicine in 2000 and conducted post-doctoral research into neurodegenerative disease at Harvard Medical School. He served as a trustee of the International Headache Society from 2015 to 2017. He currently chairs the Pan-Asian Committee of the American Headache Society, and is also actively involved in the Japanese Headache Society. His recent research interests include the biological and structural changes of trigeminal ganglion neurons in migraine pathogenesis, functional interactions between TRP channels, and cortical spreading depolarization biology.

    Professor Mamoru Shibata discloses: Honoraria for lectures from Amgen K.K., Daiichi Sankyo, Eli Lilly Japan and Otsuka Pharmaceutical.
    Prof. Christian Lampl

    Convent Hospital of the Brothers of Mercy, Linz, Austria

    Prof. Christian Lampl is head of the Department of Neurology at the Convent Hospital of the Brothers of Mercy in Linz, Austria, director of the Headache Medical Center, Linz, and chair of the Center of Integrative Medicine for Elderly at the Ordensklinikum Linz. read more

    He is the current president of the European Headache Federation (EHF) and also serves as an associate editor for the Journal of Headache and Pain (JHP). Prof. Lampl’s research is focused on the epidemiology and burden of headache; migraine aura as a possible risk factor for migraine headache; and headache, with a focus on elderly people. He has published numerous articles and contributed to several book chapters. Prof. Lampl is an ad hoc reviewer for journals such as Cephalalgia, JHP, Headache, Clinical Journal of Pain, Journal of Neurology and European Journal of Neurology.

    Professor Christian Lampl discloses: Advisory board and speaker fees from AbbVie, Lilly, Lundbeck, Novartis, Pfizer and Teva Pharmaceuticals; Consultancy fees from Lilly and Lundbeck; Grants for planning and conducting clinical trials from AbbVie, Lilly and Lundbeck.
    Dr Simy Parikh

    Thomas Jefferson University Hospital, Philadelphia, PA, USA

    Dr Simy Parikh is an assistant professor of neurology and headache medicine specialist at the Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA. read more

    Dr Parikh is board certified in neurology by the American Board of Psychiatry and headache medicine by the United Council for Neurologic Subspecialties. Her specific interests in headache medicine include spontaneous spinal cerebrospinal fluid leak, migraine, and migraine and pregnancy, on which she has published several papers. Dr Parikh is a member of the American Academy of Neurology, American Headache Society and International Headache Society, and serves on the medical advisory board of the Spinal CSF Leak Foundation. She is also interested in medical education and is the programme director of the Advanced Headache Diagnosis and Management Certificate Program at Thomas Jefferson University.

    Dr Simy Parikh discloses: Advisory board fees from Pfizer (Nurtec MONITOR Pregnancy Registry).
    Downloads

    View and download resources from this activity to support your learning and share with colleagues. Select a language to continue.

    Module 1 Slides
    Module 2 Slides 1
    Module 2 Slides 2
    Module 2 Summary
    Module 3 Slides 1
    Module 3 Slides 2
    Module 3 Summary
    Module 4 Slides
    Module 4 Summary
    Module 1 Slides
    Module 2 Slides 1
    Module 2 Slides 2
    Module 2 Summary
    Module 3 Slides 1
    Module 3 Slides 2
    Module 3 Summary
    Module 4 Slides
    Module 4 Summary
    Module 1 Slides
    Module 2 Slides 1
    Module 2 Slides 2
    Module 2 Summary
    Module 3 Slides 1
    Module 3 Slides 2
    Module 3 Summary
    Module 4 Slides
    Module 4 Summary
    CORRECT!
    Next question
    touchNEUROLOGY touchNEUROLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:

    • Headache Disorders

    European Partner

    An Introduction to Headache Disorders

    Headache disorders are among the most prevalent and incapacitating conditions worldwide, accounting for nearly three-quarters of all neurological-related disabilities. Primary headache disorders encompass migraine, tension headache, and cluster headache, while medication-overuse headache stands as the prevailing form of secondary headache. Over the past decade, significant advancements in headache management have emerged, revolutionizing the treatment landscape. Notably, novel therapeutic approaches have honed in on targeting the CGRP (calcitonin gene-related peptide) ligand or receptor, thereby reshaping the treatment paradigm for migraines and exhibiting efficacy in combatting cluster headache. Additionally, a fresh avenue of intervention comes in the form of ditans, gepants and monoclonal antibodies, with many forms of medications being delivered by different approaches such as skin patches and nasal sprays, thereby reducing patient burden. These breakthroughs hold great promise in alleviating the burden of headache disorders, fostering improved quality of life for affected individuals.

    Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from our journal touchREVIEWS in Neurology. This is complimented by a range of educational activities developed in collaboration with our leading expert faculty.

    Our supporting partners do not constitute an endorsement of the content on this page.

    Headache Disorders Content

    Headache Disorders
    Watch Time: 12 mins
    touchCLINICAL PERSPECTIVES
    Migraine prevention in the real world: Exploring the role of anti-CGRP antibodies
    Prof. Simona Sacco, Ms Elena Ruiz de la Torre, Prof. Mamoru Shibata, Prof. Christian Lampl, Dr Simy Parikh Translations available:

    Shining a light on the burden of migraine and exploring real-world evidence on anti-CGRP antibodies.

    Learning objectives
    Learning Objectives
    • Explain the impact of migraine on patient quality of life and the importance of prevention
    • Evaluate real-world data for the use of anti-CGRP antibodies for migraine prevention
    • Formulate a strategy for stopping and restarting anti-CGRP antibodies for migraine prevention
    Headache Disorders
    Developed by Touch
    Peter Goadsby, EAN 2023: Highlights in migraine
    Watch Time: 2 mins

    In this touchNEUROLOGY interview, editorial board member Prof Peter Goadsby (King’s college Hospital, London) highlights two presentations from the annual European Academy of Neurology (EAN), July 1–4, 2023, in the field of migraine; the first by Klein et al. looking at a new potential biomarker of visual snow syndrome, and the second a presentation that he […]

    Headache Disorders
    Developed by Touch
    Peter Goadsby, EAN 2023: Highlights in headache disorders
    Watch Time: 2 mins

    In this touchNEUROLOGY interview, editorial board member Prof Peter Goadsby (King’s college Hospital, London) provides an overview of his top three most important clinical trial data and hot topics presented at the annual European Academy of Neurology (EAN), July 1–4, 2023, in the field of headache disorders. He highlights two important presentations using calcitonin gene-related peptide […]

    Epilepsy, Headache Disorders, Multiple Sclerosis, Neuroimmunology, Neuromuscular Diseases, Parkinson's Disease
    Developed by Touch
    Highlights from EAN 2023!
    Watch Time: 2 mins

    touchFEATURE
    Oral migraine therapy: targeting calcitonin gene-related peptide (CGRP)
    For HCPs in: UK.
    Promotional material developed and funded by Pfizer Ltd.
    View Time: 7 mins Sponsored content

    Adverse events should be reported. Reporting forms and information can be found at
    Adverse events should also be reported to Pfizer Medical Information on 01304 616161

    Vydura®▼ (rimegepant) Prescribing Information (PI) for Great Britain (GB) and Northern Ireland (NI)

    V5 - PP-NNT-GBR-0760
    Date of Preparation: August 2023
    Headache Disorders
    Developed by Touch
    Stewart Tepper, AAN 2023: Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
    Watch Time: 3 mins

    Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) summarizes the pivotal results of the PROGRESS phase 3 trial, evaluating the efficacy, safety, and tolerability of atogepant for preventive treatment of chronic migraine (CM). This study has very important clinical indications for the use of G pants in prevention of migraine. Atogepant […]

    Headache Disorders
    Developed by Touch
    Atogepant for preventive treatment of chronic migraine, PROGRESS phase 3 trial: Richard Lipton, AAN 2023
    Watch Time: 9 mins

    Atogepant represents a relatively new class of medications called CGRP receptor antagonists, which have shown efficacy in preventing migraines. The PROGRESS phase 3 clinical trial assessed the efficacy of atogepant, an important new oral treatment option for the 8% of people with migraine who live with chronic migraine. Prof. Richard Lipton (Albert Einstein College of Medicine, […]

    Headache Disorders
    Developed by Touch
    Stewart Tepper, AAN 2023: Results from the PRODROME trial of ubrogepant for the acute treatment of migraine
    Watch Time: 4 mins

    Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) shares one the most exciting presentations from the 75th AAN Annual Meeting, 2023. The results of the PRODROME study represent a paradigm shift in headache management and the data are a very exciting advance for headache and migraine specialists. Ubrogepant for the Acute Treatment […]

    Headache Disorders
    Developed by Touch
    Stewart Tepper, AAN 2023: Significant reduction in migraine days with REN for migraine prevention: A double-blind randomized sham-controlled clinical trial
    Watch Time: 4 mins

    Migraine affects over 1 billion people worldwide causing significant disability and a socioeconomic burden. Preventive treatment is key to managing migraine, but it is often underutilized. Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) summarizes his presentation from the 75th AAN Annual Meeting, 2023. Remote electrical neuromodulation (REN), a non-pharmacological acute migraine treatment, […]

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32 social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72